DelveInsight’s “Ocular Hypertension Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of ocular hypertension, historical and forecasted epidemiology, as well as the ocular hypertension market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Discover Key Insights into the Ocular Hypertension Market with DelveInsight’s In-Depth Report @ Ocular Hypertension Market Size

 

Key Takeaways from the Ocular Hypertension Market Report

• According to DelveInsight’s epidemiology model, there were approximately 21 million prevalent cases of ocular hypertension in the 7MM in 2023, with 13 million diagnosed cases. These numbers are projected to rise throughout the study period (2020-2034).
• In 2023, the US had the highest number of diagnosed ocular hypertension cases, with approximately 5.4 million cases.
• Among the EU4 and the UK, Germany reported the highest number of diagnosed ocular hypertension cases in 2023, with nearly 1.3 million cases, followed by the UK with approximately 1.1 million cases. In contrast, Spain had the fewest, with nearly 866 thousand cases.
• Japan accounted for nearly 2.7 million diagnosed cases of ocular hypertension in 2023. This number is expected to increase throughout the study period.
• In 2023, females were more affected by ocular hypertension in the US compared to males.
• In 2023, Japan saw the highest prevalence of ocular hypertension among individuals aged 80 and above, followed by those in the 70–79 age group, 60–69 age group, 50–59 age group, and 40–49 age group.
• The leading Ocular Hypertension Companies such as Kubota Vision Inc., Otsuka Pharmaceuticals Co. Ltd, Theratocular Biotek Co., Novotech Pty Limited, Metagone Biotech Inc., Future Medicine, Novartis, Chakshu Research Inc., Jenivision Inc., Mati Therapeutics Inc., QLT Inc., Santen Inc., AbbVie, Aerie Pharmaceuticals, Qlaris Bio Inc., Nephron Pharmaceuticals, Corporation, Envisia Therapeutics, and others.
• Promising Ocular Hypertension Therapies such as NCX 470, Nyxol, Sepetaprost(DE-126/ONO-9054/STN1012600 ), LL-BMT1, PDP-716, V-GL1, NCX 470, Kinezodianone R hydrochloride, G2-TR intraocular implant containing travoprost, H-1337, AGN-193408 SR, Latanoprost ophthalmic solution, OTX-TIC, PER-001, and others.

 

Stay ahead in the Ocular Hypertension Therapeutics Market with DelveInsight’s Strategic Report @ Ocular Hypertension Market Outlook

 

Ocular Hypertension Epidemiology Segmentation in the 7MM

• Ocular Hypertension Prevalent cases
• Ocular Hypertension Diagnosed cases
• Ocular Hypertension Gender-specific prevalence Cases
• Ocular Hypertension Age-specific prevalence cases

 

Download the report to understand which factors are driving Ocular Hypertension epidemiology trends @ Ocular Hypertension Prevalence

 

Ocular Hypertension Marketed Drugs

• VYZULTA (latanoprostene bunod ophthalmic solution): Bausch + Lomb

VYZULTA is a prostaglandin analog designed to manage IOP in patients with open-angle glaucoma or ocular hypertension. This once-daily monotherapy offers a dual mechanism of action. Upon administration, VYZULTA metabolizes into two active components: latanoprost acid and butanediol mononitrate. Latanoprost acid enhances aqueous humor outflow through the uveoscleral pathway, while butanediol mononitrate releases nitric oxide to facilitate increased outflow via the trabecular meshwork and Schlemm’s canal. This combined effect helps effectively reduce IOP.

 

• RHOPRESSA: Alcon (Aerie Pharmaceuticals)/Santen Pharmaceutical

RHOPRESSA (netarsudil ophthalmic solution) is a 0.02% Rho kinase inhibitor used to treat ocular hypertension. This topical ophthalmic product is provided as a sterile, isotonic, buffered aqueous solution with a pH of approximately 5 and an osmolality of around 295 mOsmol/kg. It contains netarsudil as the active ingredient, with benzalkonium chloride (0.015%) as a preservative. Inactive components include mannitol, boric acid, sodium hydroxide for pH adjustment, and water for injection. RHOPRESSA lowers intraocular pressure (IOP) by increasing aqueous humor outflow through the trabecular meshwork, reducing aqueous humor production, and lowering episcleral venous pressure (EVP). It is approved in the US, EU, and Japan.

 

• DURYSTA: AbbVie (Allergan)

DURYSTA (bimatoprost implant) is a prostaglandin analog used to reduce IOP in patients with open-angle glaucoma or ocular hypertension. It is delivered via a single intracameral administration of a biodegradable implant containing 10 μg of bimatoprost. The implant is preloaded into a single-use applicator for easy placement directly into the anterior chamber of the eye.

 

Ocular Hypertension Emerging Drugs

• NCX 470: Nicox/Kowa

NCX 470 is an innovative eye drop formulation combining nitric oxide and bimatoprost to lower IOP through dual mechanisms. Developed using Nicox’s proprietary nitric oxide-donating technology, it targets open-angle glaucoma and ocular hypertension by delivering both nitric oxide and bimatoprost into the eye. Protected by composition of matter patents until 2029, with potential extensions in the US and EU, and formulation patents extending to 2039, NCX 470 is currently under evaluation in Phase III trials. The Phase III Mont Blanc trial has assessed the safety and efficacy of NCX 470 compared to latanoprost. Additionally, the Whistler and Denali Phase III trials are ongoing.

 

• QLS-111: Qlaris Bio

QLS-111 is a novel formulation based on an ATP-sensitive potassium (KATP) channel modulator platform, designed to lower IOP by relaxing the vessels in vascular and vascular-like tissues distal to the trabecular meshwork, reducing outflow resistance and episcleral venous pressure (EVP). QLS-111 has shown persistent IOP reduction without causing hyperemia or compromising vascular integrity.

 

• ST266: Noveome Biotherapeutics

ST266 is a cell-free biologic containing hundreds of proteins and factors involved in cellular healing, neuroprotection, and inflammation modulation. It is derived from proteins secreted by amnion-derived epithelial cells collected from full-term placentas. This secretome, rich in growth factors and cytokines, has demonstrated anti-inflammatory and neuroprotective effects in preclinical studies. The scalable manufacturing process supports production for multiple indications, with a drug master file submitted to the US FDA for investigational new drug (IND) applications.

 

Get In-Depth Knowledge on Ocular Hypertension Market Trends and Forecasts with DelveInsight @ Ocular Hypertension Treatment Market

 

Ocular Hypertension Treatment Market Landscape

The current Ocular Hypertension treatment market involves both pharmacological and surgical therapies. The ocular hypertension treatment market is segmented into various classes: prostaglandin analogs (PGAs), beta-blockers, alpha-agonists, carbonic anhydrase inhibitors, rho kinase inhibitors, and combination therapies. PGAs are the first-line therapy for primary open-angle glaucoma (POAG) due to their efficacy, minimal side effects, and once-daily dosing.

 

Scope of the Ocular Hypertension Market Report

• Coverage- 7MM
• Study Period- 2020-2034
• Ocular Hypertension Companies- Kubota Vision Inc., Otsuka Pharmaceuticals Co. Ltd, Theratocular Biotek Co., Novotech Pty Limited, Metagone Biotech Inc., Future Medicine, Novartis, Chakshu Research Inc., Jenivision Inc., Mati Therapeutics Inc., QLT Inc., Santen Inc., AbbVie, Aerie Pharmaceuticals, Qlaris Bio Inc., Nephron Pharmaceuticals, Corporation, Envisia Therapeutics, and others.
• Ocular Hypertension Therapies- NCX 470, Nyxol, Sepetaprost(DE-126/ONO-9054/STN1012600 ), LL-BMT1, PDP-716, V-GL1, NCX 470, Kinezodianone R hydrochloride, G2-TR intraocular implant containing travoprost, H-1337, AGN-193408 SR, Latanoprost ophthalmic solution, OTX-TIC, PER-001, and others.
• Ocular Hypertension Therapeutic Assessment: Ocular Hypertension current marketed and Ocular Hypertension emerging therapies
• Ocular Hypertension Market Dynamics: Ocular Hypertension market drivers and Ocular Hypertension market barriers
• Ocular Hypertension Unmet Needs, KOL’s views, Analyst’s views, Ocular Hypertension Market Access and Reimbursement

 

Unlock Strategic Insights with DelveInsight’s Comprehensive Ocular Hypertension Market Report @ Ocular Hypertension Market Drivers and Barriers

 

Table of Content

1 Key Insights

2 Report Introduction

3 Market Overview at a Glance

4 Epidemiology and Market Methodology

5 Executive Summary

6 Key Events

7 Disease Background and Overview

8 Patient Journey

9 Epidemiology and Patient Population

10 Marketed Drugs

11 Emerging Drugs

12 Ocular Hypertension: Market Analysis

13 Key Opinion Leaders’ Views

14 SWOT

15 Unmet Needs

16 Market Access and Reimbursement

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/sepsis-market